Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

PHASE3CompletedINTERVENTIONAL
Enrollment

784

Participants

Timeline

Start Date

March 2, 2016

Primary Completion Date

November 23, 2016

Study Completion Date

November 16, 2017

Conditions
Glabellar Frown Lines
Interventions
DRUG

Botulinum Toxin A

Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.

DRUG

Placebo

Injection, 0.9% sodium chloride divided in five 0.1 mL i.m. injections into glabellar area

DRUG

Botulinum Toxin A

Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area in up to 3 treatment cycles

Trial Locations (18)

10707

RZANY & HUND, Privatpraxis, Berlin

19104

Society Hill Dermatology, Philadelphia

27517

Aesthetic Solutions, Chapel Hill

35205

Total Skin And Beauty Dermatology Center, Pc, Birmingham

37215

Tennessee Clinical Research Center, Nashville

60611

DeNova Research, Chicago

64283

Rosenpark Research, Darmstadt

68144

Skin Specialists, Omaha

80111

About Skin, Greenwood Village

82319

Praxisklinik Fur Dermatologie, Hautzentrum am Starnberger See, Starnberg

91436

Clinical Testing of Beverly Hills, Encino

94115

Maas Clinic, San Francisco

Unknown

S-thetic Clinic Hamburg, Hamburg

Praxis Klinik Dr. Med. Anita Ruetter, Münster

Carpe Diem, Centre for Aesthetic Medicine, Warsaw

Clinical Research Group Sp. z o.o., Warsaw

Estederm Dr Marcin Ambroziak, Warsaw

High-Med. Przychodnia Specjalistyczna, Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Croma-Pharma GmbH

INDUSTRY

NCT02677298 - Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I | Biotech Hunter | Biotech Hunter